detinfДЕТСКИЕ ИНФЕКЦИИCHILDREN INFECTIONS2072-81072618-8139Association of Pediatricians and Infection Disease doctors10.22627/2072-8107-2018-17-3-38-46detinf-375Research ArticleВОПРОСЫ ТЕРАПИИPROBLEMS OF THERAPYОСОБЕННОСТИ ИММУННОГО ОТВЕТА И ЭФФЕКТИВНОСТЬ ИММУНОТЕРАПИИ ПРИ РОТАВИРУСНОЙ ИНФЕКЦИИ У ДЕТЕЙFEATURES OF THE IMMUNE RESPONSE AND EFFICACY IMMUNOTHERAPY FOR ROTAVIRUS INFECTION IN CHILDRENhttps://orcid.org/0000-0001-6335-0487ГорбуновС. Г.GorbunovS. G.

Горбунов  Сергей  Георгиевич - доктор медицинских наук, профессор кафедры детских инфекционных болезней.

Москва.

Moscow.

gsgsg70@mail.ruМазанковаЛ. Н.MazankovaL. N.

Мазанкова Людмила Николаевна - заведующая кафедрой детских инфекционных болезней, доктор медицинских наук, профессор.

Москва.

Moscow.

mazankova@list.ruМайковаИ. Д.MaykovaI. D.

Майкова Ирина  Дмитриевна - заместиетль главного врача ГБУЗ ДГКБ им. З.А. Башляевой ДЗМ, кандидат медицинских наук.

Москва.

 

Moscow.

maikova.id@tdgb.mosgorzdrav.ruДеминаО. И.DeminaO. I.

Дёмина Ольга Игоревна - аспирант кафедры детских инфекционных болезней.

Москва.

Moscow.

demina91@mail.ruКовальЕ. П.KovalE. P.

Коваль Екатерина  Петровна - клинический  ординатор кафедры детских инфекционных болезней.

Москва.

Moscow

katerina.gordeychik@mail.ruФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздрава РоссииРоссияRussian Medical Academy of Continuig Professional Education of the Ministry of Healthcare of the Russian FederationRussian FederationГБУЗ Детская городская клиническая больница им. З.А. Башляевой ДЗМРоссияСhildren's city clinical hospital named after Z.A. Bashlyayeva of Moscow Department of HealthcareRussian Federation2018200920181733846Copyright © Горбунов С.Г., Мазанкова Л.Н., Майкова И.Д., Демина О.И., Коваль Е.П., 20182018Горбунов С.Г., Мазанкова Л.Н., Майкова И.Д., Демина О.И., Коваль Е.П.Gorbunov S.G., Mazankova L.N., Maykova I.D., Demina O.I., Koval E.P.This work is licensed under a Creative Commons Attribution 4.0 License.https://detinf.elpub.ru/jour/article/view/375

В статье отражены изменения как клеточного, так и гуморального звеньев иммунитета при ротавирусной инфекции, а также показана корреляция между степенью выраженности иммунологических нарушений и особенностями клинического течения заболевания в детском возрасте. Наиболее значительные изменения цитокинового статуса  связаны  с повышением интерлейкина-1b, который является маркером интоксикации. Кроме того, при ротавирусной инфекции у детей снижается уровень индуцированных интерферонов a и у , что служит  обоснованием применения a2b-интерферона, входящего в состав препарата ВИФЕРОН®, содержащего также антиоксиданты витамины  Е и С. Назначение препарата ВИФЕРОН® наряду с базисной терапией, включающей пробиотические  штаммы ВВ12 и LGG, в комплекс лечебных мероприятий у детей с ротавирусной инфекцией позволяет улучшить динамику клинико-иммунологических показателей, а также сократить в 1,5 раза  количество случаев ОРВИ в течение 6 месяцев катамнестического наблюдения после острого периода заболевания.

The article reflects the changes in both cellular and humoral immunity in rotavirus infection, as well as the correlation between the degree of severity of immunological disorders and the peculiarities of the clinical course of the disease in childhood.  The most significant changes in cytokine status are associated with an increase in interleukin-1b, which is a marker of intoxication. In addition, during rotavirus infection in children reduced the level of induced interferon a and у, that justified the application of a2b-interferon that is part of the drug VIFERON®, containing also vitamins E and C. The appointment of drug VIFERON®, along with basic therapy, including the probiotic strains LGG and ВВ12 in the complex of therapeutic measures  in children with rotavirus infection allows to improve the dynamics of clinical and immunological indicators, as well as to reduce 1.5 times the number of cases of ARI within 6 months of the follow-up observations after the acute period of the disease.

ротавирусная инфекцияиммунитетцитокины2b -интерферонпробиотикидетиrotavirus infectionimmunitycytokines2b-interferonprobioticschildrenReferencesImplementing the new recommendations on the clinical management of diarrhoea: guidelines for policy makers and programme managers. WHO, 2006; 36.Implementing the new recommendations on the clinical management of diarrhoea: guidelines for policy makers and programme managers. WHO, 2006; 36.Мазанкова Л.Н., Чеботарева Т.А., Майкова И.Д., Горбунов С.Г. Цитокиновый статус и эффективность цитокинотерапии при ротавирусной инфекции у детей. Фарматека. 2015; 4: 73—77.Mazankova L.N., Chebotareva T.A., Maykova I.D., Gorbunov S.G. Cytokine status and effectiveness of cytokinotherapy in rotavirus infection in children. Pharmateca. 2015; 4: 73—77. (In Russ)Мазанкова Л.Н., Горбунов С.Г. Диагностика и лечение ротавирусной инфекции у детей раннего возраста. Фарматека. 2017; 4: 24—28.Mazankova L.N., Gorbunov S.G. Diagnosis and treatment of rotavirus infection in young children. Pharmateca. 2017; 4: 24—28. (In Russ)Тихомирова О.В., Сергеева Н.В., Сироткин А.К. Вирусные диареи у детей: особенности клинического течения и тактика терапии. Детские инфекции. 2003; 3: 7—11.Tikhomirova O.V., Sergeyeva N.V., Sirotkin A.K. Viral diarrhea in children: features of the clinical course and tactics of therapy. Detskie Infektsii = Children’s Infections. 2003; 3: 7—11. (In Russ)Deal E.M., Lahl K., Narvaez C.F., Butcher E.C., Greenberg H.B. Plasmacytoid dendritic cells promote rotavirus-induced human and murine B cell responses. J. Clin. Investigation. 2013; 123: 2464—2474.Deal E.M., Lahl K., Narvaez C.F., Butcher E.C., Greenberg H.B. Plasmacytoid dendritic cells promote rotavirus-induced human and murine B cell responses. J. Clin. Investigation. 2013; 123: 2464—2474.Lin J.-D., Feng N., Sen A., Balan M., Tseng H.-C., McElrath C., Smirnov S.V., Peng J., Yasukawa L.L., Durbin R.K., Durbin J.E., Greenberg H.B., Kotenko S.V. Distinct roles of type I and type III intestinal immunity to homologous and heterologous rotavirus infections. PLOS Pathogens. 2016; 12(4): 1—29Lin J.-D., Feng N., Sen A., Balan M., Tseng H.-C., McElrath C., Smirnov S.V., Peng J., Yasukawa L.L., Durbin R.K., Durbin J.E., Greenberg H.B., Kotenko S.V. Distinct roles of type I and type III intestinal immunity to homologous and heterologous rotavirus infections. PLOS Pathogens. 2016; 12(4): 1—29Lutz L.M., Pace C.R., Arnold M.M. Rotavirus NSP1 associates with components of the cullin ring ligase family of E3 ubiquitin ligases. J. Virology. 2016; 90(13): 6036—6048.Lutz L.M., Pace C.R., Arnold M.M. Rotavirus NSP1 associates with components of the cullin ring ligase family of E3 ubiquitin ligases. J. Virology. 2016; 90(13): 6036—6048.Davis K.A., Morelli M., Pattona J.T. Rotavirus NSP1 requires casein kinase II-mediated phosphorylation for hijacking of cullin-ring ligases. mBio. 2017; 8, Issue 4: 01213—01217.Davis K.A., Morelli M., Pattona J.T. Rotavirus NSP1 requires casein kinase II-mediated phosphorylation for hijacking of cullin-ring ligases. mBio. 2017; 8, Issue 4: 01213—01217.Qiu Y., Yang J., Wang W., Zhao W., Peng F., Xiang Y., Chen G., Chen T., Chai C., Zheng S., Watkins D.J., Feng J. HMGB1-promoted and TLR2/4-dependent NK cell maturation and activation take part in rotavirus-induced murine biliary atresia. PLOS Pathogens. 2014; 10, Issue 3: 1—15.Qiu Y., Yang J., Wang W., Zhao W., Peng F., Xiang Y., Chen G., Chen T., Chai C., Zheng S., Watkins D.J., Feng J. HMGB1-promoted and TLR2/4-dependent NK cell maturation and activation take part in rotavirus-induced murine biliary atresia. PLOS Pathogens. 2014; 10, Issue 3: 1—15.Yuan L., Wen K., Azevedo M.S.P., Gonzalez A.M., Zhang W., Saif L.J. Virus-specific intestinal IFN-producing T-cell responses induced by human rotavirus infection and vaccines are correlated with protection against rotavirus diarrhea in gnotobiotic pigs. Vaccine. 2008; 26(26): 3322—3331.Yuan L., Wen K., Azevedo M.S.P., Gonzalez A.M., Zhang W., Saif L.J. Virus-specific intestinal IFN-producing T-cell responses induced by human rotavirus infection and vaccines are correlated with protection against rotavirus diarrhea in gnotobiotic pigs. Vaccine. 2008; 26(26): 3322—3331.Azevedo M.S.P., Yuan L., Pouly S., Gonzalez A.M., Jeong K.I., Nguyen T.V., Saif L.J. Cytokine responses in gnotobiotic pigs after infection with virulent or attenuated human rotavirus. J. Virology. 2006; 80(1): 372—382.Azevedo M.S.P., Yuan L., Pouly S., Gonzalez A.M., Jeong K.I., Nguyen T.V., Saif L.J. Cytokine responses in gnotobiotic pigs after infection with virulent or attenuated human rotavirus. J. Virology. 2006; 80(1): 372—382.Yu T.H., Tsai C.N., Lai M.W., Chen C.C., Chao H.C., Lin C.W., Chiu C.H., Chen S.Y. Antigenemia and cytokine expression in rotavirus gastroenteritis in children. J. Microbioljgy, Immunology and Infection. 2012; 45: 265—270.Yu T.H., Tsai C.N., Lai M.W., Chen C.C., Chao H.C., Lin C.W., Chiu C.H., Chen S.Y. Antigenemia and cytokine expression in rotavirus gastroenteritis in children. J. Microbioljgy, Immunology and Infection. 2012; 45: 265—270.Кафарская Л.И., Ефимов Б.А., Постникова Е.А., Донских Е.Е. Особенности становления микрофлоры у детей раннего возраста. Детские инфекции. 2006; 1: 6—12.Kafarskaya L.I., Yefimov B.A., Postnikova E.A., Donskikh E.E. Features of formation of microflora in young children. Detskie Infektsii = Children’s Infections. 2006; 1: 6—12. (In Russ)Мазанкова Л.Н., Новокшонов А.А., Майкова И.Д. Микробиоценоз кишечника и иммунитет. Детские инфекции. 2007; 1: 9—12.Mazankova L.N., Novokshonov A.A., Maykova I.D. The intestinal microbiota and the immune system. Detskie Infektsii = Children’s Infections. 2007; 1: 9—12. (In Russ)Wen K., Tin C., Wang H., Yang X., Li G., Giri-Rachman E., Kocher J., Bui T., Clark-Deener S., Yuan L. Probiotic Lactobacillus rhamnosus GG enhanced Th1 cellular immunity but did not affect antibody responses in a human gut microbiota transplanted neonatal gnotobiotic pig model. PLOS one. 2014; 9, Issue 4: 1—10.Wen K., Tin C., Wang H., Yang X., Li G., Giri-Rachman E., Kocher J., Bui T., Clark-Deener S., Yuan L. Probiotic Lactobacillus rhamnosus GG enhanced Th1 cellular immunity but did not affect antibody responses in a human gut microbiota transplanted neonatal gnotobiotic pig model. PLOS one. 2014; 9, Issue 4: 1—10.Twitchell E.L., Tin C., Wen K., Zhang H., Becker-Dreps S., Azcarate-Peril M.A., Vilchez S., Li G., Ramesh A., Weiss M., Lei S., Bui T., Yang X., Schultz-Cherry S., Yuan L. Modeling human enteric dysbiosis and rotavirus immunity in gnotobiotic pigs. Gut Pathogens. 2016; 8(51): 1—18.Twitchell E.L., Tin C., Wen K., Zhang H., Becker-Dreps S., Azcarate-Peril M.A., Vilchez S., Li G., Ramesh A., Weiss M., Lei S., Bui T., Yang X., Schultz-Cherry S., Yuan L. Modeling human enteric dysbiosis and rotavirus immunity in gnotobiotic pigs. Gut Pathogens. 2016; 8(51): 1—18.Волкова Р.С., Комарова О.Н. Эффективность применения бифидумбактерина форте. Med. Market. 2000; 1: 13—14.Volkova R.S., Komarova O.N. Efficiency of application of Bifidumbacterin Forte. Med. Market. 2000; 1: 13—14. (In Russ)Костюк О.П., Чернышова Л.И., Волоха А.П. Физиологические и терапевтические свойства лактобактерий. Педиатрия. 1998; 1: 71—76.Kostyuk O.P., Chernysheva L.I., Volokha A.P. Physiological and therapeutic properties of lactobacillus. Pediatria. 1998; 1: 71—76. (In Russ)Collins M.D., Gibson G.R. Probiotics, prebiotics and synbiotics: approaches for modulating the microbial ecology of the gut. Amer. J. Clin. Nutr. 1999; 5: 1052S—1057S.Collins M.D., Gibson G.R. Probiotics, prebiotics and synbiotics: approaches for modulating the microbial ecology of the gut. Amer. J. Clin. Nutr. 1999; 5: 1052S—1057S.Gronlujul M.M., Arvilommi H., Kero P. et al. Importance of intestinal colonization in the maturation of humoral immunity in early infancy: a prospective follow up study of healthy infants aged 0—6 month. Arch. Dis. Child. Fetal. Neonatal. Ed. 2000; 3: 186—192.Gronlujul M.M., Arvilommi H., Kero P. et al. Importance of intestinal colonization in the maturation of humoral immunity in early infancy: a prospective follow up study of healthy infants aged 0—6 month. Arch. Dis. Child. Fetal. Neonatal. Ed. 2000; 3: 186—192.Лопатина Т.К., Бляхер М.С., Николаенко В.Н. Иммуномодулирующее действие препаратов-эубиотиков. Вестник РАМН. 1997; 3: 30—34.Lopatina T.K., Blyakher M.S., Nikolayenko V.N. Immunomodulatory drugs-eubiotiks. Bulletin of RAMS=Vestnik RAMN. 1997; 3: 30—34. (In Russ)Pelto L., Isolauri E., Lilius E.M. et al. Probiotic bacteria down-regulate the milk-induced inflammatory response in milk-hypersensitive subjects but have an immunostimulatory effect in healthy subjects. Clin. Exp. Allergy. 1998; 12: 1474—1479.Pelto L., Isolauri E., Lilius E.M. et al. Probiotic bacteria down-regulate the milk-induced inflammatory response in milk-hypersensitive subjects but have an immunostimulatory effect in healthy subjects. Clin. Exp. Allergy. 1998; 12: 1474—1479.Kimura K., McCartney A.L., McConnell M.A., Tannock G.W. Analysis of fecal populations of bifidobacteria and lactobacilli and investigation of the immunological responses of their human hosts to the predominant strains. Appl. Environment. Microbiol. 1997; 9: 3394—3398.Kimura K., McCartney A.L., McConnell M.A., Tannock G.W. Analysis of fecal populations of bifidobacteria and lactobacilli and investigation of the immunological responses of their human hosts to the predominant strains. Appl. Environment. Microbiol. 1997; 9: 3394—3398.Савицкая К.И., Воробьев А.А., Русанова Е.В. Роль неспорообразующих анаэробов в формировании микробного пейзажа содержимого толстой кишки у больных с воспалительными процессами разной локализации. Вестник РАМН. 1996; 2: 15—23.Savitskaya K.I., Vorobiev A.A., Rusanova E.V. The role of nonporous anaerobes in the formation of the microbial landscape of the colon contents in patients with inflammatory processes of different localization. Bulletin of RAMS=Vestnik RAMN. 1996; 2: 15—23. (In Russ)Цой И.Г., Сапаров А.С., Тимофеева И.К. Иммуностимулирующее действие лактобактерий на цитотоксичность естественных клеток киллеров и продукцию интерферона. ЖМЭИ. 1994; 6: 112—113.Tsoy I.G., Saparov A.S., Timofeyeva I.K. Immunostimulatory effect of lactobacillus on cytotoxicity of natural killer cells and interferon production. JMEI. 1994; 6: 112—113. (In Russ)Shiffrin E.J., Rochat F., Link-Amster H. et al. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J. Dairy Sci. 1995; 3: 491—497.Shiffrin E.J., Rochat F., Link-Amster H. et al. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J. Dairy Sci. 1995; 3: 491—497.Donnet-Hughes A., Rochat F., Serrant P. et al. Modulation of non-specific mechanisms of defense by lactic acid bacteria: effective dose. J. Dairy Sci. 1999; 5: 863—869.Donnet-Hughes A., Rochat F., Serrant P. et al. Modulation of non-specific mechanisms of defense by lactic acid bacteria: effective dose. J. Dairy Sci. 1999; 5: 863—869.Link-Amster H., Rochat F., Saudan K.Y. et al. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol. Med. Microbiol. 1994; 1: 55—63.Link-Amster H., Rochat F., Saudan K.Y. et al. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol. Med. Microbiol. 1994; 1: 55—63.Kishi A., Uno K., Matsubara Y. et al. Effect of the oral administration of Lactobacillus brevis subsp. coagulans on interferon-alpha producing capacity in humans. J. Amer. Coll. Nutr. 1996; 4: 408—412.Kishi A., Uno K., Matsubara Y. et al. Effect of the oral administration of Lactobacillus brevis subsp. coagulans on interferon-alpha producing capacity in humans. J. Amer. Coll. Nutr. 1996; 4: 408—412.Hessle C., Hanson L.A., Wold A.E. Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production. Clin Exp. Immunol. 1999; 2: 276—282.Hessle C., Hanson L.A., Wold A.E. Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production. Clin Exp. Immunol. 1999; 2: 276—282.Miettinen M., Vuopio-Varkila J., Varkila K. Production of human tumor necrosis factor alpha, interleukin-6 and interleukin-10 is induced by lactic acid bacteria. Infect. Immunol. 1996; 12: 5403—5405.Miettinen M., Vuopio-Varkila J., Varkila K. Production of human tumor necrosis factor alpha, interleukin-6 and interleukin-10 is induced by lactic acid bacteria. Infect. Immunol. 1996; 12: 5403—5405.Perdigon G., Vintini E., Alvarez S. et al. Study of the possible mechanisms involved in the mucosal immune system activation by lactic acid bacteria. J. Dairy Sci. 1999; 6: 1108—1114.Perdigon G., Vintini E., Alvarez S. et al. Study of the possible mechanisms involved in the mucosal immune system activation by lactic acid bacteria. J. Dairy Sci. 1999; 6: 1108—1114.Yasui H., Nagaoka N., Hayakawa K. Augmentation of anti-influenza virus hemagglutinin antibody production by Peyer’s patch cells with Bifidobacterium breve YIT4064. Clin. Diagn. Lab. Immunol. 1994; 2: 244—246.Yasui H., Nagaoka N., Hayakawa K. Augmentation of anti-influenza virus hemagglutinin antibody production by Peyer’s patch cells with Bifidobacterium breve YIT4064. Clin. Diagn. Lab. Immunol. 1994; 2: 244—246.Бондаренко В.М., Рубакова Э.И., Лаврова В.А. Иммуностимулирующее действие лактобактерий, используемых в качестве основы препаратов пробиотиков. ЖМЭИ. 1998; 5: 107—112.Bondarenko V.M., Rubakova E.I., Lavrova V.A. Immunostimulatory effect of lactobacillus used as the basis of probiotic preparations. JMEI. 1998; 5: 107—112. (In Russ)Малиновская В.В. Новый комплексный препарат Виферон и его применение в иммунореабилитации в педиатрической и акушерской практике. International Journal of Immunorehabilitation. 1998; 10: 76—84.Malinovskaya V.V. New complex drug Viferon and its application in immuno rehabilitation in pediatric and obstetric practice. International Journal of Immunorehabilitation. 1998; 10: 76—84. (In Russ)Виферон: комплексный противовирусный и иммуномодулирующий препарат для детей и взрослых (руководство для врачей под ред В.В. Малиновской). М., 2006. 87.Viferon: a comprehensive antiviral and immunomodulatory drug for children and adults (guide for doctors ed. of V.V. Malinovskaya). Moscow, 2006. 87. (In Russ)

The authors declare that there are no conflicts of interest present.